We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis (NVS) Q3 Earnings: Stock to Beat Estimates Again?
Read MoreHide Full Article
Novartis AG (NVS - Free Report) is scheduled to report third-quarter 2016 results on Oct 25.
In the last reported quarter, it recorded a positive earnings surprise of 3.39%. Overall, Novartis has posted an average negative earnings surprise of 2.38% in the four trailing quarters. Let’s see how things are shaping up for this announcement.
Why a Likely Positive Surprise?
Our proven model shows that Novartis is likely to beat earnings because it has the right combination of two key ingredients.
Zacks ESP: The Earnings Surprise Prediction or Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, stands at +0.84%. This is very meaningful and a leading indicator of a likely positive earnings surprise for shares.
Zacks Rank: Novartis carries a Zacks Rank #3 (Hold). Note that stocks with a Zacks Rank #1 (Strong Buy), #2 (Buy) and #3 have a significantly higher chance of beating earnings. The sell-rated stocks (#4 or #5), on the other hand, should never be considered going into an earnings announcement, especially when the company is witnessing negative estimate revisions.
The combination of Novartis’ favorable Zacks Rank and positive ESP makes us reasonably confident of a positive earnings beat on Oct 25.
Factors to Impact the Quarter
Novartis operates under three segments: Innovative Medicines (Pharmaceuticals), Alcon and Sandoz (Generics). Although the company expects 2016 to be a transformative year, it has been facing challenging conditions over the past few quarters.
Innovative Medicines is expected to continue being impacted by generic competition due to the genericization of Gleevec/Glivec in the U.S. The company’s ophthalmologic division, Alcon, continues to face challenges due to a slowdown in cataract equipment placements and weak sales of intraocular lenses. Going forward, we expect these factors to dampen sales at the segment. On the other hand, Novartis’ generic arm, Sandoz, in its efforts to strengthen the biosimilars portfolio and pipeline, should offset weakness in Alcon.
Last quarter, the company’s heart failure drug, Entresto, obtained a strong Class I recommendation in both the U.S. and the EU as per the heart failure treatment guidelines. These guidelines establish Entresto as the standard of care for symptomatic patients with heart failure with reduced ejection fraction (HFrEF). The company’s decision to increase spending on Entresto to build a U.S. primary care field force and add incremental medical support will drive expenses in the third quarter. Entresto sales are expected to be approximately $200 million in 2016.
In the third quarter, unfavorable movements in foreign exchange rates are estimated to impact sales by 1% and earnings by 2%.
Meanwhile, investor focus should remain on the sales ramp-up of newly launched drugs Entresto, Glatopa and Cosentyx. Main growth drivers at the oncology segment will include Jakavi, Tasigna, Promacta/Revolade, Tafinlar+Mekinist and the improved formulation of Exjade. Multiple sclerosis drug, Gilenya, should also perform well.
Here are some other health care stocks that you may want to consider, as our model shows that they too have the right combination of elements to post an earnings beat this quarter.
The Earnings ESP for ImmunoGen, Inc. is +5.41% and it carries a Zacks Rank #3. The company is scheduled to release earnings on Oct 28.
Infinity Pharmaceuticals, Inc. has an Earnings ESP of +5.81% and a Zacks Rank #1. The company is expected to report quarterly numbers on Nov 3.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novartis (NVS) Q3 Earnings: Stock to Beat Estimates Again?
Novartis AG (NVS - Free Report) is scheduled to report third-quarter 2016 results on Oct 25.
In the last reported quarter, it recorded a positive earnings surprise of 3.39%. Overall, Novartis has posted an average negative earnings surprise of 2.38% in the four trailing quarters. Let’s see how things are shaping up for this announcement.
Why a Likely Positive Surprise?
Our proven model shows that Novartis is likely to beat earnings because it has the right combination of two key ingredients.
Zacks ESP: The Earnings Surprise Prediction or Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, stands at +0.84%. This is very meaningful and a leading indicator of a likely positive earnings surprise for shares.
Zacks Rank: Novartis carries a Zacks Rank #3 (Hold). Note that stocks with a Zacks Rank #1 (Strong Buy), #2 (Buy) and #3 have a significantly higher chance of beating earnings. The sell-rated stocks (#4 or #5), on the other hand, should never be considered going into an earnings announcement, especially when the company is witnessing negative estimate revisions.
The combination of Novartis’ favorable Zacks Rank and positive ESP makes us reasonably confident of a positive earnings beat on Oct 25.
Factors to Impact the Quarter
Novartis operates under three segments: Innovative Medicines (Pharmaceuticals), Alcon and Sandoz (Generics). Although the company expects 2016 to be a transformative year, it has been facing challenging conditions over the past few quarters.
Innovative Medicines is expected to continue being impacted by generic competition due to the genericization of Gleevec/Glivec in the U.S. The company’s ophthalmologic division, Alcon, continues to face challenges due to a slowdown in cataract equipment placements and weak sales of intraocular lenses. Going forward, we expect these factors to dampen sales at the segment. On the other hand, Novartis’ generic arm, Sandoz, in its efforts to strengthen the biosimilars portfolio and pipeline, should offset weakness in Alcon.
Last quarter, the company’s heart failure drug, Entresto, obtained a strong Class I recommendation in both the U.S. and the EU as per the heart failure treatment guidelines. These guidelines establish Entresto as the standard of care for symptomatic patients with heart failure with reduced ejection fraction (HFrEF). The company’s decision to increase spending on Entresto to build a U.S. primary care field force and add incremental medical support will drive expenses in the third quarter. Entresto sales are expected to be approximately $200 million in 2016.
In the third quarter, unfavorable movements in foreign exchange rates are estimated to impact sales by 1% and earnings by 2%.
Meanwhile, investor focus should remain on the sales ramp-up of newly launched drugs Entresto, Glatopa and Cosentyx. Main growth drivers at the oncology segment will include Jakavi, Tasigna, Promacta/Revolade, Tafinlar+Mekinist and the improved formulation of Exjade. Multiple sclerosis drug, Gilenya, should also perform well.
NOVARTIS AG-ADR Price and EPS Surprise
NOVARTIS AG-ADR Price and EPS Surprise | NOVARTIS AG-ADR Quote
Stocks to Consider
Here are some other health care stocks that you may want to consider, as our model shows that they too have the right combination of elements to post an earnings beat this quarter.
Amgen Inc. (AMGN - Free Report) is expected to report results on Oct 26. The company has an Earnings ESP of +1.79% and a Zacks Rank #3. the complete list of today’s Zacks #1 Rank stocks here.
The Earnings ESP for ImmunoGen, Inc. is +5.41% and it carries a Zacks Rank #3. The company is scheduled to release earnings on Oct 28.
Infinity Pharmaceuticals, Inc. has an Earnings ESP of +5.81% and a Zacks Rank #1. The company is expected to report quarterly numbers on Nov 3.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>